Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | HRH1 | P35367 | 3/20 | 0.35 |
| ▸ | CSF1R | P07333 | 10/20 | 0.35 |
| ▸ | FYN | P06241 | 3/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FRK | P42685 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628001 | 0.81 | FYN (0.46) | CDK2DRD2HTR2AHRH1CSF1R | |
| SCHEMBL15864803 | 0.79 | CDK2 (0.42) | CDK2DRD2HTR2AHRH1CSF1R | |
| SCHEMBL15864503 | 0.75 | FYN (0.58) | CDK2CSF1RFYN | |
| SCHEMBL5357512 | 0.75 | CRHR1 (0.32) | — | |
| SCHEMBL12411075 | 0.74 | CDK2 (0.47) | CDK2DRD2HTR2AHRH1CSF1R | |
| SCHEMBL31080610 | 0.74 | CSF1R (0.39) | CDK2DRD2HTR2AHRH1CSF1R | |
| SCHEMBL5325336 | 0.73 | HCAR3 (0.44) | CDK2DRD2HTR2AHRH1CSF1R | |
| SCHEMBL18274603 | 0.73 | CSF1R (0.43) | CDK2DRD2HTR2AHRH1CSF1R | |
| SCHEMBL5206051 | 0.72 | CDK2 (0.50) | CDK2DRD2HTR2AHRH1CSF1R | |
| SCHEMBL20774859 | 0.69 | CDK2 (0.35) | CDK2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-07 | — | — | US | disclosed |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CDK2 1095/4885DRD2 176/4885HTR2A 22/4885 |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CDK2 1095/4885DRD2 176/4885HTR2A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.